Background: Brivaracetam (BRV), eslicarbazepine acetate (ESL), lacosamide (LCM), and perampanel (PER) have been recently marketed as adjunctive treatments for focal onset seizures. To date, no randomized controlled trial (RCT) has directly compared BRV with ESL, LCM, or PER. Purpose: To compare BRV with the other add-on AEDs in patients with uncontrolled focal epilepsy, estimating their efficacy and tolerability through an adjusted, common-reference based indirect comparison meta-analysis. Methods: We systematically searched RCTs in which add-on treatment with ESL or LCM in patients with focal onset seizures have been compared with placebo. Efficacy and tolerability outcomes were considered. Random-effects Mantel-Haenszel meta-analyses were performed to obtain odds ratios (ORs) for the efficacy of BRV, LCM, ESL, or PER versus placebo. Adjusted indirect comparisons were then made between BRV and the other three AEDs using the obtained results, comparing the minimum and the highest effective recommended daily dose of each drug. Results: Seventeen RCTs, with a total of 4971 patients were included. After adjusting for dose-effects, indirect comparisons showed no difference between BRV and LCM, ESL, or PER for responder rate and seizure freedom. Lower adverse events were observed with high dose BRV compared to high dose ESL or PER, but no difference was found in withdrawing because of adverse events. Conclusions: Indirect comparisons do not demonstrate a significant difference in efficacy between add-on BRV and LCM, ESL, or PER in focal epilepsy, and might suggest a better tolerability of BRV than ESL, and possibly also PER, at the highest effective recommended dose.
Introduction
Epilepsy is one of the most common neurologic disorders, affecting almost 70 million people in the world [1] . Despite the introduction of third-generation antiepileptic drugs (AEDs), approximately 30% of patients with epilepsy continue having seizures [2, 3] . In patients where monotherapy inadequately controls seizure, an adjunctive treatment may be necessary. However, intolerable adverse effects and pharmacological interaction may burden polytherapy. Hence, there is still an ongoing need for more novel AEDs with higher efficacy and better tolerability [4] .
In last years, five AEDs have been approved as add-on treatments for patients with focal epilepsy: retigabine (ezogabine), eslicarbazepine acetate (ESL), lacosamide (LCM), perampanel (PER), and -more recently -brivaracetam (BRV). The use of retigabine has been nonetheless severely limited by the frequent occurrence of blue skin discoloration and eye abnormalities characterized by pigment changes in the retina following treatment with this AED [5] .
Among the newest AEDs, BRV is thought to exert its antiepileptic effect by selectively binding to synaptic vesicle protein 2A (SV2A) -a mechanism of action shared by its precursor levetiracetam -with subsequent modulation of release of neurotransmitters into the synapse [6] . Brivaracetam has been shown to be more effective than levetiracetam in seizure control in animal models [6] .
To date, no randomized controlled trial (RCT) has directly compared the efficacy of BRV with ESL, LCM or PER used as add-on treatments for focal epilepsy. To overcome this lack of information or insufficient evidence from direct head-to-head comparisons, sophisticated statistical methods have been developed to indirectly estimate the effect of two or more healthcare treatments or interventions. These methods are termed as indirect comparison, in that they exploit data from separate studies, differently from direct comparisons which use data from individual arms within the same head-to-head comparative RCTs. Basically, there are two kinds of indirect comparisons: namely, naive and adjusted indirect comparisons. While the former approach treats arms from different trials as if they were from the same trials and is therefore contraindicated for meta-analyzing data from RCTs, performing instead better for observational trials, the latter approach, using a comparator "in common", is more statistically rigorous and powerful.
However, the validity of these adjusted indirect comparisons depends on the methodological quality and similarity of the included trials [7] . On the other hand, they may provide useful information where data from direct comparisons do not exist. An indirect-comparison meta-analysis has previously assessed the efficacy and tolerability of LCM, PER, ESL, and retigabine [8] , without including the BRV, whose use in humans has been approved only recently.
We, therefore, decided to compare BRV with LCM, ESL, or PER in patients with focal epilepsy uncontrolled by monotherapy, indirectly estimating their efficacy and tolerability through a common-reference based indirect comparison meta-analysis.
Methods
This review was guided by a written pre-specified protocol describing research questions, review methods, and a plan for data extraction and synthesis. The protocol is available online at: http://www.crd.york.ac.uk/PROSPERO/printPDF.php?RecordID=37279&UserID=1662.
Inclusion and exclusion criteria
Randomized controlled trials comparing add-on BRV (50 or 200 mg), LCM (200 or 400 mg), ESL (800 or 1200 mg) or PER (8 or 12 mg) versus placebo in the treatment of focal epilepsy (simple focal, complex focal or secondary generalized tonic-clonic seizures) in patients of any age were included.
Patients from any age group and diagnosed with focal epilepsy (simple focal, complex focal or secondary generalized tonic-clonic seizures) were included. Trials were not excluded on the basis of dose, duration of treatment, or length of follow-up.
Trials evaluating flexible-dose of AED were excluded.
Search methods
A comprehensive review of the literature was performed to minimize publication bias.
Electronic databases were searched using the following search strategy: "(brivaracetam OR lacosamide OR eslicarbazepine OR perampanel) AND epilepsy AND randomi*".
Following electronic databases and data sources were searched: Most recent systematic reviews reporting data on BRV [9] [10] [11] , ESL [8, 12] , LCM [8, 13] , and PER [8] .
There were no language restrictions. All searches were conducted on 13th March 2016.
Study selection and methodological quality assessment
Trials were scrutinized, and the methodological quality of all included studies evaluated. Study selection was done independently by two reviewers (FB and RN) and cross-checked for accuracy. Any disagreement was resolved through discussion.
Quality assessment included the following aspects of methodology: study design, definition and clinical relevance of outcomes, type of control, method of allocation concealment, total study duration, completeness of follow-up, intention-to-treat analysis, data concerning adverse effects, risk of bias, and conflict of interests. The randomized trials were judged on the reported method of allocation concealment and on the risk of bias as outlined in the Cochrane Handbook for Systematic Reviews of Interventions Version 5. 
Type of outcomes
The following outcomes were chosen:
1. 50% responder rate, defined as the proportion of patients with 50% or greater reduction in seizure frequency in the treatment period compared to the pre-randomization baseline period ("responders"); 2. Proportion of patients achieving seizure freedom during treatment period; 3. Proportion of patients experiencing any TEAE during treatment period; 4. Proportion of patients with TEAEs leading to study/treatment discontinuation.
For each outcome, an intention-to-treat primary analysis was made.
Data extraction
The following trial data were extracted: main study author and age of publication; country; type of participants (children and/or adults); total number, age, and sex of participants for each treatment group; seizure type; intervention details (dose, route of administration); proportion of patients with 50% or greater reduction in seizure frequency (responders) in each group; proportion of patients achieving seizure freedom in each group; proportion of patients with any treatment-emergent adverse event (TEAE), defined as an adverse events occurring after the first intake of study treatment in the double-blind phase, in each group; proportion of patients with TEAEs leading to discontinuation in each group. Data were extracted independently by two reviewers (FB and RN) and cross-checked for accuracy. Any disagreement was resolved through discussion.
Statistical analyses

Conventional meta-analyses
We performed conventional meta-analyses RCTs comparing add-on BRV (50 or 200 mg), LCM (200 or 400 mg), ESL (800 or 1200 mg) or PER (8 or 12 mg) versus placebo. Results were pooled by using random effects, inverse variance, weighted meta-analysis [14] . Each outcome was analyzed by calculating ORs for each trial with the uncertainty being expressed using 95% confidence intervals (CI), and for each outcome a weighted treatment effect across trials was calculated. A random effects model was used assuming that the different studies are estimating different, yet related, treatment effects. Homogeneity among trial results was evaluated using a standard Chi-squared test rejecting the hypothesis of homogeneity with p-value lower than 0.10. Assessment of statistical heterogeneity was supplemented by the I-squared (I 2 ) statistic that measures the total variation across studies due to heterogeneity [14] .
Adjusted indirect-comparison common reference-based metaanalyses
The ORs obtained in the conventional meta-analyses were then used to perform indirect comparisons between BRV and other AEDs. Indirect-comparison common reference-based meta-analyses were carried out using the frequentist method [15] adopted in previous reviews [7, [15] [16] [17] [18] [19] [20] . According to this method, indirect comparisons were performed from the results of the direct comparisons using a common intervention control (placebo) estimated by conventional random-effects meta-analyses. In the indirect comparison meta-analyses, an OR > 1 indicates that the outcome is more likely with add-on BRV than with other add-on AEDs. A p-value of 0.05 was considered to be statistically significant.
To take differences in efficacy due to different doses (see below, Section 4) into account, indirect comparisons were performed comparing following daily dosages: BRV 50 mg versus LCM 200 mg, or ESL 800 mg, or PER 8 mg (minimum effective recommended daily doses) and BRV 200 mg versus LCM 400 mg, or ESL 1200 mg, or PER 12 mg (highest effective recommended daily doses).
Furthermore, to take into account clinical heterogeneity due to different severity of epilepsy estimated by number of concomitant AEDs, we carried out a sensitivity analysis limiting the trials to those enrolling <10% of patients on !3 AEDs.
Furthermore, we planned to perform a sensitivity analysis including only RCTs where responder rate was calculated by comparing seizure frequency during baseline with that during the maintenance period (and not during the entire double-blind phase).
Analyses were conducted using RevMan 5.3 (conventional meta-analysis for each AED), Excel and R 2.15.1 (common reference-based indirect comparison meta-analysis). Graphic representations of results of indirect comparisons were reported adopting the methodology used by Zaccara et al. [17] .
Results
The search strategy described above yielded 845 results (157 MEDLINE, 145 CENTRAL, 10,721 ClinicalTrials.gov, 471 EMBASE). The pharmaceutical companies Eisai and UCB Pharma were contacted (March 2016), and no additional unpublished trials were found.
After excluding duplicate studies (322) and reading the title and the abstract, 18 studies were provisionally selected.
After having read the full text, we excluded one study (see below); hence we included 17 studies with a total of 4971 patients with focal epilepsy (Fig. 1) .
Four RCTs compared BRV 50 mg versus placebo (305 versus 304 patients, respectively) [21] [22] [23] [24] , and one compared BRV 200 mg/day versus placebo (250 versus 261 patients, respectively) [25] . One BRV study was excluded because it administered flexibledose of BRV, ranging from 20 to 150 mg/day [26] . Three studies reported data on PER 8 mg versus placebo (431 patients allocated to PER versus 441 randomized to placebo) [27] [28] [29] , and three on PER 12 mg versus placebo (292 patients randomized to PER 12 mg and 267 patients allocated to placebo) [27, 29, 30] . Five RCTs reported data on ESL 800 mg or 1200 mg versus placebo (498 patients randomized to ESL 800 mg, 530 patients to ESL 1200 mg, and 557 to placebo) [31] [32] [33] [34] [35] . Three RCTs compared LCM 200 or 400 mg with placebo (267 patients randomized to LCM 200 mg, 466 to LCM 400 mg, and 359 to placebo) [36] [37] [38] . Characteristics of included studies are reported in Table 1 . 
Risk of bias in included studies
Details on the risk of bias for included studies are provided as Supplementary material.
All studies were double-blind RCT adopting adequate random sequence generation and allocation concealment (low risk of selection bias). Performance and detection bias were also low in each included study. No study except one reported incomplete outcomes (low risk of attrition bias). In the one study, however, there was a high proportion of missing data (11/47 from the placebo group, 8/50 from the ESL once daily group, and 12/37 from the ESL twice daily group; unclear risk of attrition bias, due to lack of reasons for missing data) [31] .
Conventional meta-analysis per AED
Results are reported as Supplementary material. 3.3. Indirect comparison reference-based meta-analysis 3.3.1
. 50% responder rate
Common reference-based indirect comparisons by combining meta-analyses of AEDs showed no difference between BRV and LCM, ESL or PER both at minimum and at highest effective recommended daily dosages (Table 2A ; Fig. 2A ).
Seizure freedom
Indirect comparisons showed no difference between BRV and LCM, ESL or PER both at minimum and at highest effective recommended daily dosages (Table 2B ; Fig. 2A ).
Treatment-emergent adverse events
Common reference-based indirect comparisons by combining meta-analyses of AEDs showed a statistically significant lower risk (Table 2C ; Fig. 2B ).
Treatment-emergent adverse events leading to study/treatment discontinuation
Common reference-based indirect comparisons by combining meta-analyses of AEDs showed no difference between BRV and LCM, ESL or PER both at minimum and at highest effective recommended daily dosages in terms of TEAEs leading to study/ treatment discontinuation (Table 2D ; Fig. 2A ).
Sensitivity analysis
A sensitivity analysis was carried out to evaluate the effect of clinical heterogeneity in terms of number of concomitant AEDs. All the 5 included RCTs on BRV enrolled <10% of patients on !3 AEDs. We therefore conducted a sensitivity analysis excluding seven trials (four PER [27] [28] [29] [30] , one ESL [34] , and two LCM [37, 38] ) enrolling >10% of patients on !3 AEDs.
Sensitivity analysis showed no difference between BRV and LCM or PER both at minimum and at highest effective recommended daily dosages in 50% responder rate (Table 3A ; Fig. 3A ), in seizure freedom (Table 3B ; Fig. 3A) , and in TEAEs (Table 3C ; Fig. 3A ). Brivaracetam 200 mg was associated with lower TEAEs overall, and with lower TEAEs leading to discontinuation than ESL 1200 mg (Table 3C and D ; Fig. 3B) ; this difference was not demonstrated at minimum effective recommended daily dosage (BRV 50 mg/day versus ESL 800 mg/day) (Fig. 3A) .
We also carried out a sensitivity analysis including only RCTs where responder rate was calculated by comparing seizure frequency during baseline with that during the maintenance period (i.e., excluding RCTs where responder rate was calculated during the entire double-blind period, titration and (Table 3E ; Fig. 3A ).
Discussion
Indirect comparison meta-analyses using placebo as a common comparator did not demonstrate a significant difference in efficacy Some statistically significant differences in indirect comparisons were found only in treatment-emergent adverse events.
Table 3
Results of common reference-based indirect comparisons. Sensitivity analyses limiting the trials to those enrolling <10% of patients on !3 AEDs (outcomes A-D) and limiting the trials to those calculating 50% responder rate by comparing seizure frequency during baseline with that during the maintenance period (outcome E). A. 50% responder rate; B. Seizure freedom; C. Treatment-emergent adverse events; D. Treatment-emergent adverse events leading to drug discontinuation; E. 50% responder rate.
Sensitivity analyses
A. 50% responder rate, studies with proportion of patients with !3 concomitant antiepileptic drugs lower than 10% between add-on BRV and LCM, ESL, or PER in patients with focal epilepsy both considering the minimum (BRV 50 mg/day, ESL 800 mg/day, LCM 200 mg/day, PER 8 mg/day) and the highest effective recommended daily dose (BRV 200 mg/day, ESL 1200 mg/ day, LCM 400 mg/day, PER 12 mg/day). Concerning tolerability, a lower risk of TEAEs was found only in indirect comparisons between BRV 50 mg versus PER 8 mg, and between BRV 200 mg versus ESL 1200 mg or PER 12 mg, but no differences were observed for TEAEs leading to study/treatment discontinuation both considering the minimum and the highest effective recommended daily dose of all drugs.
Comparisons between these dosages were made to take into account dose-effects. However, to date there is no information on equi-effective doses of these drugs. For this reason, we compared only the minimum and the highest effective recommended doses as reported in the summary of product characteristics of the drugs approved by European Medicines Agency and Food and Drug Administration [39] [40] [41] [42] [43] [44] , as made in a previous indirect-comparison meta-analysis on tolerability of ESL, LCM, and oxcarbazepine [17] . Due to lack of information on equi-effective doses of these drugs, we decided not to perform dose-adjusted indirect comparisons for intermediate dosages (BRV 100-150 mg/day, PER 10 mg). The doses of ESL 400 mg/day and LCM 600 mg/day were not considered in subgroup analyses on drug dosages, as the former was not shown to be more effective than placebo in seizure control whereas the latter had an unfavorable risk/benefit profile, so that these dosages have not been recommended by the drug regulatory agencies and hence not included in the summary of product characteristics.
Comparisons in efficacy and tolerability between BRV and the other novel AEDs taken into consideration were made indirectly using data obtained from individual comparisons versus placebo, due to lack of head-to-head RCTs. Therefore, our conclusions are based on indirect evidence.
Although in most cases the results obtained from indirect comparison meta-analyses are consistent with direct comparisons (93%) [6] , the validity of indirect comparisons depends on the methodological quality and similarity of the RCTs being indirectly compared [6] . As no RCTs directly comparing BRV with ESL, LCM or PER have been conducted so far, we are unable to evaluate a possible discrepancy between results of direct and indirect comparisons.
Indirect comparisons between two different interventions are estimated using a common comparator (placebo, in our case). They may provide useful information when direct evidence from headto-head comparisons is not available. However, indirect comparisons are not randomized, but are more akin to observational studies; may suffer from confounding; and their precision is smaller than that from direct comparisons (variance from indirect comparisons is wider).
Hence, the validity of indirect comparisons depends on the methodological quality and similarity of the RCTs being indirectly compared (homogeneity and similarity assumption) [6] .
In our study, all trials were sufficiently homogeneous, both clinically and methodologically: all patients were adults with focal epilepsy uncontrolled by monotherapy. Studies were also very similar in terms of mythology adopted (adequate allocation concealment and randomization procedures; blinding; duration of baseline and treatment periods; types of outcomes being considered; data reported on an intention-to-treat basis).
To reduce methodological heterogeneity across trials, we decided not to include one RCT administering flexible-dose of BRV [26] . Furthermore, we found differences in number of daily administrations in RCTs on ESL: in all these studies except one [31] , ESL was administered once daily. Hence, to reduce methodological heterogeneity, in the study conducted by Elger et al. [31] , only patients randomized to ESL once daily were included (those allocated to receive ESL twice daily were not included).
Another possible source of methodological heterogeneity across trials is the number of concomitant AEDs, which may have affected the accuracy of outcome results. This issue has been specifically assessed in sensitivity analyses conducted excluding those trials enrolling >10% of patients on !3 AEDs.
A second assumption, which needs to be fulfilled for valid indirect comparisons, is, that the trials, which are indirectly compared, should be similar for moderators of relative Some statistically significant differences in indirect comparisons were found only in treatment-emergent adverse events and treatment-emergent adverse events leading to drug discontinuation (higher with ESL 1200 mg than with BRV 200 mg).
intervention effect (i.e., similarity assumption). In our study, global 50% responder rate in the control (placebo) arm was 20.9%. Similar results were found for all AEDs at different dosages (see Supplementary material 3).
To assess efficacy, we chose 50% responder rate and seizure freedom. Comparative results on 50% responder rate should be read and interpreted with caution. Actually, responder rate can be calculated either by comparing seizure frequency during baseline with that during the maintenance period or during the entire double-blind period (titration and maintenance) [45] . This is a possible source of methodological heterogeneity across studies which we took into account by performing a sensitivity analysis including only RCTs calculating responder rate in the maintenance period compared to baseline [21] [22] [23] [24] [25] [27] [28] [29] 32, [35] [36] [37] [38] . In this analysis no difference was found between BRV and LCM or PER both at minimum and at highest effective recommended daily dosages.
Compared to responder rate, seizure freedom is a stronger outcome measure. However, in all included studies only a few subjects achieved seizure freedom. Consequently, it is possible that the statistical analyses on this efficacy outcome lacked sufficient statistical power to detect a difference [46] . The risk of false negative results in indirect comparisons is therefore high, as shown by the finding that several network meta-analyses conducted in this field came to inconclusive results [8, 18, [47] [48] [49] .
Regarding tolerability, indirect comparisons showed lower risk of TEAEs for BRV 50 mg versus PER 8 mg, and for BRV 200 mg compared to ESL 1200 mg or PER 12 mg, but no differences were observed for TEAEs leading to study/treatment discontinuation both considering the minimum and the highest effective recommended daily dose for all drugs. These data might therefore suggest a possible better tolerability profile of high dose BRV compared to high dose ESL or PER, which nonetheless needs to be confirmed by direct head-to-head RCTs. However, the number of patients with adverse events as a tolerability outcome measure is heavily influenced by characteristics of each single trial, as shown by a strong correlation between this outcome measure in patients treated with placebo and this outcome measure in patients treated with the active drug [49] . Furthermore, the lack of difference in discontinuation due to TEAEs between these three drugs (a more robust measure of tolerability) suggests that, even if present, a better tolerability profile of high dose BRV compared to high dose ESL or PER, might not be of great clinical relevance. Conversely, sensitivity analyses conducted only on those trials enrolling <10% of patients on !3 AEDs shows that BRV 200 mg is significantly less associated with overall TEAEs and with TEAEs leading to discontinuation than ESL 1200 mg. These contrasting results are probably due to the confounding effect of concomitant AEDs on the assessment of tolerability profile of a novel drug tested as an adjunctive therapy. Results of sensitivity analysis, however, seem to suggest that in patients with lower number of concomitant AEDs, BRV at the highest effective recommended dose might be better tolerated than high dose ESL.
Apart from efficacy and tolerability, other aspects including frequency of administration (unlike LCM and BRV, ESL and PER can be administered only once daily), pharmacokinetic properties with risk of drug interactions, tolerability profile, and patients' preferences should all be taken into account when choosing between these drugs.
In conclusion, indirect comparison meta-analysis do not demonstrate a significant difference in efficacy between BRV compared to LCM, ESL or PER, and might suggest a better tolerability than ESL, and possibly also PER, when these drugs are used at the highest effective recommended dose. Although we found no clinically or methodologically relevant discrepancies or significant statistical heterogeneity across included trials, our results are based on indirect evidence which provides higher grade of uncertainty than that from direct comparison. Ideally, future direct head-to-head trials directly comparing these AEDs should be conducted to draw definite conclusions on comparative efficacy and tolerability of BRV with LCM, ESL, or PER. However, it is unlikely that RCTs directly comparing novel AEDs will be conducted, as drug companies would not carry the risk of performing a comparison which may prove unfavorable for the own test AED.
